CRISPR-Cas9: Current Status and Applications - Literature Review

 

CRISPR-Cas9: Current Status and Applications - Literature Review

By: Keerthana Bellary

Abstract

Genome editing technologies have revolutionized biotechnology by enabling precise modifications to DNA sequences. Among these, CRISPR-Cas9 stands out for its efficiency and versatility in manipulating genetic material. Originally adapted from bacterial defense mechanisms, CRISPR-Cas9 utilizes a guide RNA (gRNA) to direct the Cas9 enzyme to specific DNA sequences, facilitating targeted modifications such as gene knockout, insertion, or correction. This review explores the current landscape and future prospects of CRISPR-Cas9, focusing on its applications in medicine, agriculture, and biotechnology. Ergo, CRISPR-Cas9 has transformed genetic research and application domains, offering unprecedented opportunities for genomic interventions. Future efforts are directed towards enhancing specificity, broadening applicability across diverse organisms, and addressing regulatory and ethical frameworks to maximize its possible benefits while decreasing risks.

Background 

Genome editing is a technique that scientists utilize to alter an organism's DNA with precision. This technology enables the addition, removal, or modification of genetic material at specific locations within the genome, leading to advancements in medicine, research, and biotechnology. One of the most recent forms of genome editing is CRISPR-Cas9 which has revolutionized the field of genetic engineering. CRISPR, Clustered Regularly Interspaced Short Palindromic Repeats, and its associated Cas9 protein enable precise modifications to DNA with accuracy and efficiency.  By using this molecular tool, scientists are able to edit genes within living organisms, paving the way for advancements in research, agriculture, and biotechnology. CRISPR works by utilizing a guide RNA (gRNA) to direct the Cas9 protein to a specific DNA sequence, the target sequence, in the genome. Once the gRNA binds to the target sequence, the Cas9 protein acts as molecular scissors, breaking the double strand in DNA. The cell then attempts to repair the break, typically using one of two mechanisms: non-homologous end joining, which can introduce small insertions or deletions, or homology-directed repair, which can use a provided template to make exact genetic changes.

Methodology

This literature review used a systematic search strategy to collect relevant studies on CRISPR-Cas9, focusing on articles published from 2015 to 2023. Key databases, including ScienceDirect, Nature Protocols, and Nature Biotechnology, were searched using keywords like "CRISPR-Cas9," "gene editing," and "future applications." The inclusion criteria included peer-reviewed articles, reviews, and case studies that discuss both current uses and potential future developments in areas such as medicine, agriculture, and biotechnology. The selection process involved screening titles and abstracts first, followed by a full-text review to ensure relevance. Key findings, methods, and gaps in the literature were extracted from the selected studies about CRISPR-Cas9. Results were organized thematically, grouping advancements into areas like disease applications, ethical issues, and technological innovations. Limitations included potential biases in publication, language restrictions, and the exclusion of non-peer-reviewed sources, which may affect the completeness of the review. Overall, this structured approach aimed to provide a clear overview of the current status and future applications of CRISPR-Cas9 technology.

The Use of CRISPR-Cas9 and its Ethical Challenges

The CRISPR–Cas9 system has changed the game for genetic editing in eukaryotic cells. In January 2013, five research teams announced their successful results, with key work from George Church and Feng Zhang. Effective DNA editing involves steps like optimizing codons and adding a signal for the nucleus. The Cas9 protein, mainly studied from Streptococcus pyogenes, has a complex structure with two main parts: the target recognition lobe and the nuclease lobe. The first detailed studies of Cas9's structure were published in February 2014, showing its intricate design.

Ethical issues about gene editing, especially in embryos, became major concerns. The first gene therapy trials began in 1990, highlighting both potential benefits and risks. The case of Jesse Gelsinger raised alarms about the dangers of gene therapy. Important ethical guidelines, like the Nuremberg Code, were established to protect research subjects. In November 2018, Jiankui He caused a global stir by claiming to have created genetically modified twins, raising serious ethical questions. This prompted the need for stricter rules on editing human embryos. In Russia, Denis Rebrikov also expressed plans to modify genes. Despite these controversies, CRISPR–Cas9 is commonly used for editing somatic cells. Clinical trials have explored its use for various conditions, including sickle cell disease and cancer. The high costs of CRISPR treatments make widespread use challenging. As of 2020, researchers are investigating many potential applications for CRISPR–Cas9, including genetic and infectious diseases. The technology has sparked important discussions about ethics and safety. Ongoing studies continue to expand the possibilities of gene editing.

CRISPR/Cas9 technology has transformed genetic editing in mammalian cells, helping researchers study gene functions and understand diseases better. However, even though it is generally precise, off-target effects (OTEs) can occur, leading to unintended DNA changes. Various factors, such as where the DNA is located, the type of cells used, and the conditions of the experiment, can affect these OTEs. While it’s easy to track on-target edits using different tests, identifying OTEs usually requires broader genome-wide methods. Techniques like GUIDE-seq and Digenome-seq can find these off-target effects but often require significant resources. Researchers can minimize OTEs by using specific design tools and engineered components.

The Inner Workings of CRISPR-Cas9 

            Cas13a, originating from Leptotrichia shahii, is a CRISPR tool that targets single-stranded RNA using specific guide RNA (sgRNA), showing potential for detecting RNA viruses and regulating gene expression. In contrast, CRISPR/Cas9, pioneered in a 2016 clinical trial, successfully edited genes in human T cells, demonstrating promising safety and feasibility. The evolution of Cas9 variants aims to improve specificity and broaden its applications beyond traditional gene editing methods. CRISPR/Cas9 relies on sgRNA to direct Cas9 to target DNA, inducing double-stranded breaks essential for genetic modifications. Cas9 nickase variants and Cas12a (Cpf1) offer alternative mechanisms and functionalities for precise genome editing. Delivery methods for CRISPR components include plasmids, mRNA, and Cas9 ribonucleoproteins (RNPs), with emerging strategies exploring exosomes for enhanced cellular uptake. Functional categories of CRISPR tools include DNA cleavage via Cas9, gene regulation using dCas9 (inactive Cas9), and advanced base editing technologies like CBEs (cytosine base editors) and ABEs (adenine base editors), which correct single-base mutations without causing double-strand breaks. Base-editing techniques have evolved to enable precise modifications, with prime editors (PEs) facilitating targeted base substitutions and insertions, significantly expanding gene editing capabilities. CRISPR also facilitates gene expression regulation and epigenetic modifications through dCas9, capable of activating (CRISPRa) or repressing (CRISPRi) specific genes without altering the DNA sequence directly. Modified dCas9 fused with transcriptional activators or repressors provides versatile tools for studying gene function and exploring therapeutic applications. Epigenetic modifications using CRISPR/dCas9 loaded with enzymes like DNMT3A and P300 further enhance its potential to modify gene expression patterns.         

The CRISPR/Cas13a system in bacteria defends against RNA viruses by recognizing and cutting RNA using its HEPN nuclease domain. Unlike Cas9, Cas13a retains RNase activity but with reduced specificity, causing collateral cleavage of unintended RNAs. RNA interference (RNAi) also knocks down RNA but has off-target effects. CRISPR/Cas13a tools offer RNA knockdown with lower off-target effects, using catalytically inactive dCas13a. This system also detects RNA, as seen in the SHERLOCK system using a fluorescent reporter upon RNA cleavage, now enhanced with RNA amplification for sensitive applications like SARS-CoV-2 detection.

Delivering CRISPR systems in vivo faces challenges like stability, tissue targeting, and uptake. Viral vectors like AAV and lentiviruses are common but limited by cargo capacity and genome integration risks. Lipid-based carriers, including lipid nanoparticles (LNPs), are promising for their simplicity and stability, though they often favor liver targeting. Polymer-based nanoparticles are advantageous for low immunogenicity and customizable targeting. Exosomes, natural vesicles, are explored for CRISPR delivery due to their biocompatibility and ability to transfer biomolecules between cells with minimal immune response. Engineered exosomes like GEDEX and exosomeRNP improve delivery efficiency and specificity, particularly for liver diseases. Gold nanoparticles (AuNPs) are customizable for enhanced tumor targeting and controlled CRISPR component release. Biomimetic nanomaterials, using cell membranes or biofilms, evade immune response and target specific tissues for therapeutic use. Combining delivery strategies like composite LNPs or polymeric nanoparticles optimizes gene-editing efficiency across tissues and diseases. This approach shows CRISPR's potential in precision medicine by offering targeted treatments for genetic and infectious diseases.

The CRISPR/Cas13a system in bacteria defends against RNA viruses by recognizing and cutting RNA using its HEPN nuclease domain. Unlike Cas9, Cas13a retains RNase activity but with reduced specificity, causing collateral cleavage of unintended RNAs. RNA interference (RNAi) also knocks down RNA but has off-target effects. CRISPR/Cas13a tools offer RNA knockdown with lower off-target effects, using catalytically inactive dCas13a. This system also detects RNA, as seen in the SHERLOCK system using a fluorescent reporter upon RNA cleavage, now enhanced with RNA amplification for sensitive applications like SARS-CoV-2 detection. Delivering CRISPR systems in vivo faces challenges like stability, tissue targeting, and uptake. Viral vectors like AAV and lentiviruses are common but limited by cargo capacity and genome integration risks. Lipid-based carriers, including lipid nanoparticles (LNPs), are promising for their simplicity and stability, though they often favor liver targeting. Polymer-based nanoparticles are advantageous for low immunogenicity and customizable targeting. Exosomes, natural vesicles, are explored for CRISPR delivery due to their biocompatibility and ability to transfer biomolecules between cells with minimal immune response. Engineered exosomes like GEDEX and exosomeRNP improve delivery efficiency and specificity, particularly for liver diseases. Gold nanoparticles (AuNPs) are customizable for enhanced tumor targeting and controlled CRISPR component release. Biomimetic nanomaterials, using cell membranes or biofilms, evade immune response and target specific tissues for therapeutic use. Combining delivery strategies like composite LNPs or polymeric nanoparticles optimizes gene-editing efficiency across tissues and diseases. This approach shows CRISPR's potential in precision medicine by offering targeted treatments for genetic and infectious diseases.

CRISPR-Cas9 in Treating Diseases

CRISPR-Cas9 is an incredible form of biotechnology that has made many impacts in connection to various diseases and provided forms of therapy to lessen their consequences. Some include Cancer, Liver Diseases, Cardiovascular Diseases, FDA-Approved Clinical Treatments, and Transthyretin Amyloidosis among many other diseases. 

CRISPR/Cas9 technology is used in cancer treatment to target genes like P53, Notch, and PD-L1 within tumor cells, aiming to modify or silence them to inhibit tumor growth. Specialized nanoparticles are designed to deliver gene-editing tools directly to tumor cells, enhancing precision and reducing unintended effects. Photothermal therapy, using nanomaterials activated by infrared light, selectively destroys tumor cells, particularly in low-oxygen environments where tumors are less tolerant to heat. This approach improves treatment effectiveness while minimizing damage to surrounding healthy tissue. Overall, CRISPR/Cas9 in cancer therapy shows promise for more targeted treatments with fewer side effects.

CRISPR/Cas9 is employed in treating liver diseases such as liver fibrosis and hepatitis B virus (HBV) infection by targeting specific genes and pathways involved in disease progression. Liver cell-derived exosomes are utilized as carriers for delivering CRISPR/Cas9 systems, ensuring precise gene editing within targeted cells with minimal immune response. This method holds significant potential for treating liver fibrosis by activating specific hepatocyte genes and inhibiting HBV replication effectively. Using exosomes as delivery vehicles enhances the precision and efficiency of CRISPR-based therapies for complex liver diseases, paving the way for innovative treatment strategies.

CRISPR/Cas9 technology is investigated for treating cardiovascular diseases by targeting genes related to cardiomyocyte proliferation and vascular smooth muscle cell function. Challenges in delivering nanoparticles to the heart and blood vessels, due to high blood flow and pressure, are addressed to improve treatment outcomes. This approach aims to restore cardiac function by precisely altering gene expression in cardiomyocytes and vascular cells, potentially offering new treatment options for conditions like atherosclerosis and myocardial hypertrophy. CRISPR/Cas9 holds promise for developing targeted therapies that address the underlying causes of cardiovascular diseases, aiming for long-term improvements in patient outcomes.

CRISPR/Cas9 technology is utilized in FDA-approved clinical treatments, particularly in diagnostics for detecting SARS-CoV-2 infections with high sensitivity and specificity. The development of simplified methods such as STOPCovid.v2, with STOP standing for SHERLOCK Testing in One Pot, demonstrates CRISPR-based assays' potential to revolutionize disease detection and management, especially during pandemics. In genetic disorders such as sickle cell disease and β-thalassemia, CRISPR/Cas9 shows promising results in correcting genetic mutations and restoring normal hemoglobin production in clinical trials. These advancements underscore CRISPR/Cas9's role in advancing precision medicine, offering new hope for patients with complex genetic conditions.

CRISPR-based gene-editing drugs like NTLA-2001 show promise in treating transthyretin amyloidosis by targeting and reducing mutant TTR gene expression in liver cells. This approach effectively lowers TTR protein levels without significant side effects, potentially providing a curative treatment for the disease. Clinical trials have demonstrated NTLA-2001's ability to reduce TTR concentrations in patients, highlighting its potential as a transformative therapy for transthyretin amyloidosis. CRISPR/Cas9's precision in gene editing and its ability to target specific disease-causing mutations underline its role in advancing personalized medicine for genetic disorders.

In conclusion, CRISPR-Cas9 has been a tremendously useful tool in gene editing and biotechnology, aiding in numerous medical and scientific fields. It has not only transformed the pre-existing knowledge of biotechnology and molecular biology, but has laid the groundwork for more advancements to come in the future. The ability of CRISPR-Cas9 to target specific mutations in genes and improve genomes is due to its complex systems, numerous proteins and enzymes, and universal applications. Many studies continue on CRISPR-Cas9 and adjacent biotechnological tools, giving scientists the ability to further improve the technology and find more ways to make the process more efficient. In conclusion, CRISPR-Cas9 is leading genetic research, set to revolutionize medicine and biotechnology with its precise capabilities and transformative potential.

Discussion

CRISPR-Cas9 has deeply impacted genetic engineering and genomic research by providing a precise and efficient tool for targeted genome editing. The literature review underscores its diverse applications: in biomedical research, it enables the study of gene function, modeling of genetic diseases, and potential therapies like cancer treatment; in agriculture, it offers avenues to enhance crop yield, disease resistance, and stress tolerance in plants; and in biotechnology, it supports the creation of engineered organisms for industrial applications, such as biofuel production and environmental remediation. However, challenges such as off-target effects, ethical concerns regarding germline editing, and the need for improved delivery methods remain significant. Looking forward, research aims to enhance specificity, expand applications to epigenome editing and therapeutic regulation, and establish intricate regulatory frameworks to guide responsible use. CRISPR-Cas9 continues to lend transformative advancements across biotechnology, medicine, and agriculture, though ongoing work is vital to address its technical and ethical challenges.

 

 

 

 

 

 

 

 

 

 

 

References

Gostimskaya, I. (2022, August 15). CRISPR–Cas9: A History of Its Discovery and Ethical Considerations of Its Use in Genome Editing. NCBI. Retrieved July 11, 2024, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377665/

Jiang, F., & Doudna, J. A. (2017, March 30). CRISPR Protocols and Methods. Springer Nature Experiments. Retrieved July 11, 2024, from https://experiments.springernature.com/techniques/crispr

Kimberland, M. L., Hou, W., Alfonso-Pecchio, A., Wilson, S., Rao, Y., Zhang, S., & Lu, Q. (2018, October 20). Strategies for controlling CRISPR/Cas9 off-target effects and biological variations in mammalian genome editing experiments. ScienceDirect. Retrieved July 12, 2024, from https://www.sciencedirect.com/science/article/abs/pii/S0168165618306060

Li, T., Yang, Y., Qi, H., Cui, W., Zhang, L., Fu, X., He, X., Liu, M., Li, P., & Yu, T. (2023, January 16). CRISPR/Cas9 therapeutics: progress and prospects. Signal Transduction and Targeted Therapy. Retrieved June 12, 2024, from https://www.nature.com/articles/s41392-023-01309-7

Nji Tizi Taning, C., Van Eynde, B., Yu, N., Ma, S., & Smagghe, G. (2017, April). CRISPR/Cas9 in insects: Applications, best practices and biosafety concerns. ScienceDirect. https://www.sciencedirect.com/science/article/abs/pii/S0022191016303134

Ran, F. A., & Hsu, P. D. (2023, October 24). Genome engineering using the CRISPR-Cas9 system. natureprotocols. https://www.nature.com/articles/nprot.2013.143

Redman, M., King, A., Watson, C., & King, D. (2016, April 8). What is CRISPR/Cas9? - PMC. NCBI. Retrieved July 12, 2024, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975809/

Shi, J., Wang, E., Milazzo, J. P., Wang, Z., Kinney, J. B., & Vakoc, C. R. (2015, May 11). Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. Nature Biotechnology. Retrieved July 12, 2024, from https://www.nature.com/articles/nbt.3235

Tavakoli, K., Pour-Aboughadareh, A., Kianersi, F., Poczai, P., Etminan, A., & Shooshtari, L. (2021, July 6). Applications of CRISPR-Cas9 as an Advanced Genome Editing System in Life Sciences. NCBI. Retrieved July 11, 2024, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245484/

Wilson, O., & Wilson, L. O. (2018, July 11). The Current State and Future of CRISPR-Cas9 gRNA Design Tools. Frontiers. Retrieved July 11, 2024, from https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.00749/full